{
  "id": 14733039,
  "title": "FDA ‘reset’ continues with new plan for reviewing rare disease drugs",
  "url": "https://urgent.news/2026/10/15/fda-reset-continues-with-new-plan-for-reviewing-rare-disease-drugs-14733039",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-15T15:23:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/fda-rare-disease-framework-initiative-drug-development/833080/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Healthcare Dive",
        "title": "FDA ‘reset’ continues with new plan for reviewing rare disease drugs",
        "url": "https://urgent.news/2026/10/15/fda-reset-continues-with-new-plan-for-reviewing-rare-disease-drugs",
        "published": "2026-10-15T15:23:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}